The Evolution of Lymphangioleiomyomatosis (LAM) Management: From Hormonal Manipulation to Targeted Inhibition of the Mammalian Target of Rapamycin (mTOR) Pathway. RSD 2025, 14 (4), e4614448656. https://doi.org/10.33448/rsd-v14i4.48656.